Abstract
There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Current Radiopharmaceuticals
Title: Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Volume: 2 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Abstract: There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030214
DOI https://dx.doi.org/10.2174/1874471010902030214 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain
Medicinal Chemistry Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Synthesis and Anticancer Evaluation of some Newer 2, 5-Disubstituted-1,3, 4-Oxadiazole Analogues
Letters in Drug Design & Discovery Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry Chemopreventive Properties and Molecular Mechanisms of the Bioactive Compounds in Hibiscus Sabdariffa Linne
Current Medicinal Chemistry Recent Developments on Synthesis of Indole Derivatives Through Green Approaches and Their Pharmaceutical Applications
Current Organic Chemistry Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design DNA Microarrays: Tools for the 21st Century
Combinatorial Chemistry & High Throughput Screening Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Synthesis and Reactivity of 6,8-Dibromo-2-ethyl-4H-benzo[d][1,3]oxazin-4-one Towards Nucleophiles and Electrophiles and Their Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry